Inj, nipocalimab-aahu, 3 mg
Products billed under this code include Imaavy.
Payment limit per 3 MG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Imaavy.
Payment limit per 3 MG, by effective quarter, 1Q26 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Imaavy | Janssen Biotech, Inc. | 57894-0800-01 | 100 | $3,232.10 |
| Imaavy | Janssen Biotech, Inc. | 57894-0801-01 | 400 | $12,928.40 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $32.321 | −$0.247 | 3 MG | Inj, nipocalimab-aahu, 3 mg | v1, posted September 17, 2026 |
| 3Q26 | $32.568 | −$0.102 | 3 MG | Inj, nipocalimab-aahu, 3 mg | v1, posted September 15, 2026 |
| 2Q26 | $32.67 | −$0.073 | 3 MG | Inj, nipocalimab-aahu, 3 mg | v1, posted September 15, 2026 |
| 1Q26 | $32.743 | – | 3 MG | Inj, nipocalimab-aahu, 3 mg | v1, posted September 15, 2026 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.